Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta‐analysis

@article{Wang2018PharmacologicTT,
  title={Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta‐analysis},
  author={F-F Wang and Y Wu and Y-H Zhu and Tao Ding and Rachel L. Batterham and Fan Qu and Paul J Hardiman},
  journal={Obesity Reviews},
  year={2018},
  volume={19},
  pages={1424 - 1445}
}
Women with polycystic ovary syndrome (PCOS) are almost three times more likely to be obese than those without PCOS. However, we have no specific interventions to induce weight loss so far and rely on drugs used to treat other symptoms of the syndrome or obesity in the general population. 
Polycystic Ovary Disease and Obesity: Leptin, Weight-loss Medication, and Bariatric Surgery
  • J. Burgart
  • Medicine
  • Clinical obstetrics and gynecology
  • 2020
TLDR
In patients with severe obesity, bariatric surgery is often used when other methods have been unsuccessful and has shown promising results for improving health and fertility in patients with polycystic ovary disease. Expand
Weight management strategies for patients with PCOS: current perspectives
TLDR
This work aimed to summarize available evidence of different weight-reducing interventions in PCOS and outline the gaps in current knowledge and recommend areas for further research, to allow informing the guidelines to make PCOS specific evidence-based recommendations. Expand
Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics.
TLDR
Further research in PCOS is needed to better understand the fundamental basis of the disorder, to ameliorate obesity, to correct hyperandrogenism, ovulation, hyperinsulinemia, and to optimize metabolic homeostasis. Expand
Medical treatment and comorbidity in polycystic ovary syndrome: An updated review
TLDR
The present article gives an update regarding established and upcoming medical treatment for PCOS and for comorbidities of PCOS. Expand
Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes
ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in premenopausal women. Insulin resistance and glucose intolerance are very prevalent metabolic complications inExpand
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
TLDR
Metabolic, hormonal, and reproductive primary outcomes should be uniformly addressed, to tailor future targeted treatment approaches, according to the patient phenotype and needs, to improve long-term therapeutic outcomes in this population of overweight and obese women with polycystic ovary syndrome. Expand
Endometrial function in women with polycystic ovary syndrome: a comprehensive review.
TLDR
There is sufficient evidence to support that endometrial function is altered in women with PCOS, whether clinical features of PCOS affect the endometrium, and whether there are evidence-based interventions to improveendometrial dysfunction in PCOS women. Expand
The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis
  • J. J. Ge, D. J. Wang, W. Song, S. M. Shen, W. Ge
  • Medicine
  • Journal of Endocrinological Investigation
  • 2021
TLDR
It is indicated that liraglutide and metformin have the similar effects in the treatment of overweight/obese PCOS patients, but it is necessary to master the correct medication method to reduce the occurrence of adverse reactions. Expand
Altered Thyroid Function amongst the Infertile Insulin Resistant Women with Polycystic Ovarian Syndrome
Background: Polycystic ovarian syndrome (PCOS) is a hormonal disorder common among women of the child-bearing age. Likewise, women with PCOS are more likely to be obese or overweight, which may beExpand
Effectiveness of Non-Pharmacological Interventions for Overweight or Obese Infertile Women: A Systematic Review and Meta-Analysis
TLDR
Nonpharmacological interventions could have a positive effect on the pregnancy and natural conception rates, whereas it is unclear whether they improve the live birth rate. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 80 REFERENCES
Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study.
TLDR
Although there are favorable trends toward hyperandrogenism with metformin, these must be balanced against the increased rate of gastrointestinal side effects, which were associated with an improved quality of life. Expand
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome
TLDR
Treatment will reduce the mean IR in overweight women with polycystic ovarian syndrome and it is not known if the IR variability is also reduced. Expand
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome
TLDR
The effects of long‐term metformin and flutamide, an antiandrogen drug, added alone or in combination with a low‐calorie diet, on body weight and fat distribution, androgens, metabolic parameters and clinical status in obese women with PCOS were investigated. Expand
The effect of obesity on polycystic ovary syndrome: a systematic review and meta‐analysis
TLDR
It is suggested that prevention and treatment of obesity is important for the management of PCOS and central obesity was associated with higher fasting insulin levels. Expand
Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome.
TLDR
Responsiveness to weight loss in overweight/obese PCOS women varies considerably and more than one third of women may achieve full recovery, adding new perspectives to the impact of obesity on the pathophysiology of PCOS. Expand
Obesity and PCOS: implications for diagnosis and treatment.
  • R. Legro
  • Medicine
  • Seminars in reproductive medicine
  • 2012
TLDR
Although most treatments of obesity, with the exception of bariatric surgery, achieve modest reductions in weight and improvements in the PCOS phenotype, encouraging weight loss in the obese patient remains one of the front-line therapies. Expand
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
TLDR
Metformin does not improve weight loss or menstrual frequency in obese patients with PCOS, and weight loss alone through lifestyle changes improves menstrual frequency. Expand
Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
TLDR
Lifestyle + metformin is associated with lower BMI and subcutaneous adipose tissue and improved menstruation in women with PCOS compared with lifestyle ± placebo over 6 months, suggesting the combination of lifestyle with meetformin has a role to play in weight management. Expand
Lifestyle changes in women with polycystic ovary syndrome.
TLDR
Lifestyle intervention improves body composition, hyperandrogenism (high male hormones and clinical effects) and insulin resistance in women with PCOS, and provided benefits when compared to minimal treatment for secondary reproductive, anthropometric and reproductive outcomes. Expand
Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial
TLDR
The aims of this study were to determine the effect of combined orlistat and conventional hypo caloric diet compared to diet alone in overweight and obese women with PCOS. Expand
...
1
2
3
4
5
...